Werewolf Therapeutics, Inc. — Director's Dealing 2021

Apr 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2021-04-29

Reporting Person: HBM Healthcare Investments (Cayman) Ltd. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (625995)		Direct

Footnotes

F1: The Series B Preferred Stock is convertible into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.